Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.
The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.
The data so far do not appear to justify quite this much excitement.
As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.